Companies
Kelp Blue
15-year, 6,400-ha giant-kelp licence, >200 t harvested in 2025; an XPRIZE CDR finalist with an independent atdepth MRV methodology, targeting 30,000 t C/yr by 2025 and >1M t by 2050; planning the world's first commercial blue bond (N$1.4 bn on the Namibian Stock Exchange).
- Country
- Netherlands
World's first commercial blue bond
XPRIZE CDR finalist + MRV
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| aquaculture-seafood | ✓ | ✓ | ✓ | ✓ |
| blue-carbon-restoration | ✓ | ✓ | — | ✓ |
Regulatorsepareachfdaadememoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2020 (2020-01-01) | caplight.com |
| Headquarters | Amsterdam, Netherlands (2026-08-31) | xprize.org |
| Production site | Lüderitz, Namibia (2024-07-22) | namibian.com.na |
| Capacity | 7 million litres of biostimulants per annum target for 2026 (2026-08-31) | greentech.nl |
| Headcount | 53 to 92 employees in Namibia; 400 projected in Namibia by 2027 (2026-08-31) | namibian.com.na |
| Revenue | €3 million forecasted for 2026; €5 million targeted for 2027 (2026-07-16) | thebrief.com.na |
| Funding | $2 million total funding reported; plans for up to $80 million via blue bond program (2026-08-31) medium confidence | caplight.com |
| Certification | ISO 9001, CE registration, and EcoCert certification (2026-08-31) | kelp.blue |
| Regulatory approval | 15-year commercial license for 6,400-hectare site in Namibia; Environmental Clearance Certificate; product approved in over 10 countries (2024-07-22) | namibian.com.na |
Independent sources: caplight.com · greentech.nl · namibian.com.na · thebrief.com.na · xprize.org
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Algae & macroalgae (seaweed) | aquaculture-seafood | Medium | → |
| Blue carbon | blue-carbon-restoration | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.